Trial Profile

Phase 1 Study of Autologous Tris-CAR-T Cell Locoregional Immunotherapy for Recurrent Glioblastoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 24 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous chimeric antigen receptor T cell therapy Tasly Pharmaceutical Group (Primary)
Indications Glioblastoma
Focus Adverse reactions

Most Recent Events

16 Apr 2025 According to Tasly Pharmaceuticals, Inc. media release, the company has received IND approval from China's NMPA to commence a clinical trial of P-134 for recurrent glioblastoma.
27 Jan 2024 Status changed from not yet recruiting to recruiting.
07 Feb 2023 Planned initiation date changed from 1 Nov 2022 to 1 May 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com